Table 1.
Proportion of women and menenrolled on trials leading to U.S. Food and Drug Administration cancer drug approvals between July 2008 and June 2018
| Cancer type | Trials, n | Women enrolled, n (%) | Men enrolled, n (%) | Total enrolled, n |
|---|---|---|---|---|
| All cancers a | 222 | 51,847 (47.2) | 57,995 (52.8) | 109,842 |
| All cancers, sex‐specific excluded | 186 | 31,743 (40.3) | 47,097 (59.7) | 78,840 |
| Leukemia | 28 | 3,431 (40.4) | 5,054 (59.6) | 8,485 |
| Lymphoma | 27 | 3,079 (43.7) | 3,965 (56.3) | 7,044 |
| Multiple myeloma | 11 | 2,330 (43.2) | 3,065 (56.8) | 5,395 |
| Lung b | 35 | 6,877 (40.3) | 10,202 (59.7) | 17,079 |
| Colorectal | 8 | 2,235 (39.9) | 3,362 (60.1) | 5,597 |
| Pancreas c | 4 | 863 (43.6) | 1,115 (56.4) | 1,978 |
| Kidney | 11 | 1,529 (27.3) | 4,062 (72.7) | 5,591 |
| Bladder | 6 | 559 (28.9) | 1,373 (71.1) | 1,932 |
| Melanoma | 18 | 4,175 (42.0) | 5,760 (58.0) | 9,935 |
| Thyroid | 5 | 670 (45.1) | 816 (54.9) | 1,486 |
a
145 patients and 6 trials with missing sex data have been excluded.
b
There were no small cell lung cancer trials in this trial cohort.
c
Includes adenocarcinoma and neuroendocrine tumors of the pancreas.